StockNews.com Begins Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR)

StockNews.com started coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) in a report published on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock.

Eiger BioPharmaceuticals Price Performance

Eiger BioPharmaceuticals has a one year low of $1.10 and a one year high of $43.35. The firm has a market cap of $2.55 million, a price-to-earnings ratio of -0.03 and a beta of 1.83. The firm’s 50-day moving average price is $4.77 and its 200-day moving average price is $6.98.

Eiger BioPharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.